OncoResponse wraps Series A with $22.5M; Plotting IPO, BerGenBio partners with Merck on cancer combos
→ The immuno-oncology antibody discovery company OncoResponse, created by MD Anderson and Theraclone Sciences, just completed a long-running Series A with $22.5 million. The …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.